Our bodies are composed of tens of trillions of cells, and within each cell is DNA (genes) — a blueprint that records life information, determining our growth, metabolism, health conditions, and even disease risks.
Genetic testing involves analyzing DNA sequences to identify genetic variations that affect health, helping doctors and researchers make more accurate diagnoses, assess risks, and even select the most appropriate treatment methods.
Among these, NGS (Next-Generation Sequencing) is the most advanced genetic testing technology available today. It can analyze a large number of genes at once, providing rapid and accurate genome interpretation. NGS is widely applied in precision oncology, genetic disease diagnosis, and pharmacogenomics (drug response evaluation).
CancerFree Biotech, in collaboration with the UK-based Nonacus Ltd., introduces the Galeas Tumor testing project. Tumor testing project. By combining cutting-edge technology and precision medicine, it offers a new perspective on tumor analysis.
Unlike traditional pathology that uses tissue biopsies, Galeas CTC leverages our proprietary E.V.A. (Ex Vivo Avatar) platform to detect amplified and cultured circulating tumor cells (CTCs), offering three key advantages.
Traditional tissue biopsies only reflect local tissue conditions, while liquid biopsy cfDNA (circulating free DNA) mainly originates from fragments of dead tumor cells, providing limited information. CancerFree’s culture technology focuses on highly malignant tumor cells, delivering a more complete analysis of tumor behavior.
CTCs cultured using the E.V.A. platform accurately reflect the dynamic characteristics of tumors, aiding physicians and patients in making more precise treatment decisions.
Compared to traditional biopsies, our method reduces invasive burden on patients and opens new possibilities for tumor research and personalized medicine.
E.V.A. Platform
Cultured CTC
◯◯ ◯◯ ◯
Cancer patients with recurrence or metastasis
Advanced cancer patients without standard treatment options
Patients unresponsive to standard therapies
Patients with rare or undiagnosed cancers
Patients planning to undergo targeted or immunotherapy post-surgery
Includes Single Nucleotide Variations (SNVs), Copy Number Variations (CNVs), and Insertions/Deletions (INDELs) among the 519 genes
Genes include those related to hereditary cancers, pediatric cancer genes, and glioma-associated 1p/19q co-deletion
Genes include those related to hereditary cancers, pediatric cancer genes, and glioma-associated 1p/19q co-deletion
Includes known fusion mutations: ALK, BRAF, EGFR, FGFR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, RET, ROS1, TMPRSS2
■ Variant Annotation by MH Guide (Molecular Health, Germany). Comprehensive analysis of genetic testing results for clinical reference
■ Data sources includes renowned international journals, ASCO, ESMO, NCCN clinical guidelines, and databases, data updated month
■ Compliance EU IVDR, CAP/CLIA (analytical laboratories), ISO62304, ISO62366, EN 14971, ISO27001, GDPR & HIPAA
Circulating tumor cell culture
Report generation takes approximately six weeks
Our bodies are composed of tens of trillions of cells, and within each cell is DNA (genes) — a blueprint that records life information, determining our growth, metabolism, health conditions, and even disease risks.
Genetic testing involves analyzing DNA sequences to identify genetic variations that affect health, helping doctors and researchers make more accurate diagnoses, assess risks, and even select the most appropriate treatment methods.
Among these, NGS (Next-Generation Sequencing) is the most advanced genetic testing technology available today. It can analyze a large number of genes at once, providing rapid and accurate genome interpretation. NGS is widely applied in precision oncology, genetic disease diagnosis, and pharmacogenomics (drug response evaluation).
CancerFree Biotech, in collaboration with the UK-based Nonacus Ltd., introduces the Galeas Tumor testing project. By combining cutting-edge technology and precision medicine, it offers a new perspective on tumor analysis.
Unlike traditional pathology that uses tissue biopsies, Galeas CTC leverages our proprietary E.V.A. (Ex Vivo Avatar) platform to detect amplified and cultured circulating tumor cells (CTCs), offering three key advantages.
CancerFree Biotech, in collaboration with the UK-based Nonacus Ltd., introduces the Galeas Tumor testing project. Tumor testing project. By combining cutting-edge technology and precision medicine, it offers a new perspective on tumor analysis.
Unlike traditional pathology that uses tissue biopsies, Galeas CTC leverages our proprietary E.V.A. (Ex Vivo Avatar) platform to detect amplified and cultured circulating tumor cells (CTCs), offering three key advantages.
Traditional tissue biopsies only reflect local tissue conditions, while liquid biopsy cfDNA (circulating free DNA) mainly originates from fragments of dead tumor cells, providing limited information. CancerFree’s culture technology focuses on highly malignant tumor cells, delivering a more complete analysis of tumor behavior.
CTCs cultured using the E.V.A. platform accurately reflect the dynamic characteristics of tumors, aiding physicians and patients in making more precise treatment decisions.
Compared to traditional biopsies, our method reduces invasive burden on patients and opens new possibilities for tumor research and personalized medicine.
Traditional tissue biopsies only reflect local tissue conditions, while liquid biopsy cfDNA (circulating free DNA) mainly originates from fragments of dead tumor cells, providing limited information. CancerFree’s culture technology focuses on highly malignant tumor cells, delivering a more complete analysis of tumor behavior.
CTCs cultured using the E.V.A. platform accurately reflect the dynamic characteristics of tumors, aiding physicians and patients in making more precise treatment decisions.
Compared to traditional biopsies, our method reduces invasive burden on patients and opens new possibilities for tumor research and personalized medicine.
◯◯ ◯◯ ◯
Cancer patients with recurrence or metastasis
Advanced cancer patients without standard treatment options
Patients unresponsive to standard therapies
Patients with rare or undiagnosed cancers
Patients planning to undergo targeted or immunotherapy post-surgery
◯◯ ◯◯ ◯
Cancer patients with recurrence or metastasis
Advanced cancer patients without standard treatment options
Patients unresponsive to standard therapies
Patients with rare or undiagnosed cancers
Patients planning to undergo targeted or immunotherapy post-surgery
Includes Single Nucleotide Variations (SNVs), Copy Number Variations (CNVs), and Insertions/Deletions (INDELs) among the 519 genes
Supports immunotherapy, reporting Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB)
Genes include those related to hereditary cancers, pediatric cancer genes, and glioma-associated 1p/19q co-deletion
Includes known fusion mutations: ALK, BRAF, EGFR, FGFR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, RET, ROS1, TMPRSS2
Includes Single Nucleotide Variations (SNVs), Copy Number Variations (CNVs), and Insertions/Deletions (INDELs) among the 519 genes
Supports immunotherapy, reporting Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB)
Genes include those related to hereditary cancers, pediatric cancer genes, and glioma-associated 1p/19q co-deletion
Includes known fusion mutations: ALK, BRAF, EGFR, FGFR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, RET, ROS1, TMPRSS2
■ Variant Annotation by MH Guide (Molecular Health, Germany). Comprehensive analysis of genetic testing results for clinical reference
■ Data sources includes renowned international journals, ASCO, ESMO, NCCN clinical guidelines, and databases, data updated month
■ Compliance EU IVDR, CAP/CLIA (analytical laboratories), ISO62304, ISO62366, EN 14971, ISO27001, GDPR & HIPAA
■ Variant Annotation by MH Guide (Molecular Health, Germany). Comprehensive analysis of genetic testing results for clinical reference
■ Data sources includes renowned international journals, ASCO, ESMO, NCCN clinical guidelines, and databases, data updated month
■ Compliance EU IVDR, CAP/CLIA (analytical laboratories), ISO62304, ISO62366, EN 14971, ISO27001, GDPR & HIPAA
Circulating tumor cell culture
Report generation takes approximately six weeks
Circulating tumor cell culture
Report generation takes approximately six weeks
© 2025 All Right Reserved
We aspire to be a guardian of cancer patients and a partner to medical professionals.
